Penumbra, Inc. (NYSE:PEN) Files An 8-K Submission of Matters to a Vote of Security Holders

Penumbra, Inc. (NYSE:PEN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.

Story continues below

Submission of Matters to a Vote of Security Holders.

(a)

Penumbra, Inc. (“Penumbra” or the “Company”) held its Annual Meeting of Stockholders on June 6, 2018 (“Annual Meeting”). Proxies for the Annual Meeting were solicited to Regulation14A of the Securities Exchange Act of 1934, as amended. At the close of business on the record date, April 11, 2018, there were 34,254,315 shares outstanding and entitled to vote, and 31,559,439 shares were voted in person or by proxy on the proposals described below.

(b)

At the Annual Meeting, Penumbra’s stockholders voted on the following four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2018. The number of votes cast with respect to each proposal was as indicated below:

1)

Election of Class III Directors.The following nominees were elected to serve as Class III directors, each to serve until the 2021 annual meeting of stockholders and until their successors are duly elected and qualified, based on the following results of voting:

Nominee

Votes For

VotesWithheld

BrokerNon-Votes

Adam Elsesser

21,588,102

3,984,581

5,986,756

Harpreet Grewal

20,755,487

4,817,196

5,986,756

2)

Ratification of Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the independent registered public accounting firm for Penumbra for the fiscal year ending December 31, 2018 was ratified based on the following results of voting:

Votes For

Votes Against

Abstentions

Broker Non-Votes

30,962,576

569,047

27,816

N/A

3)

Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers.The compensation of the Company’s Named Executive Officers was approved, on an advisory basis, based on the following results of voting:

Votes For

Votes Against

Abstentions

Broker Non-Votes

25,247,149

310,480

15,054

5,986,756

4)

Approval of the Penumbra, Inc. OUS Employee Stock Purchase Rebate Plan.The Penumbra, Inc. OUS Employee Stock Purchase Rebate Plan was approved based on the following results of voting:

Votes For

Votes Against

Abstentions

Broker Non-Votes

25,558,263

7,317

7,103

5,986,756


About Penumbra, Inc. (NYSE:PEN)

Penumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company’s peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.

An ad to help with our costs